Astrazeneca AB has synthesized pyraolo-and triazolo-azinone compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of neurological disorders.
Incyte Corp. has described bicyclic amine compounds acting as cyclin-dependent kinase 12 (CDK12) inhibitors reported to be useful for the treatment of cancer.
Abbisko Therapeutics Co. Ltd. has divulged pyrazole derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Immunophage Biomedical Co. Ltd. has identified ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, and inflammatory, autoimmune and metabolic disorders.
Enanta Pharmaceuticals Inc. has synthesized spirocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Convelo Therapeutics Inc. and Genentech Inc. have disclosed 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.
Arvinas Operations Inc. and Genentech Inc. have described proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) targeting moiety through a linker reported to be useful for the treatment of cancer, including non-small-cell lung cancer.
St. Jude Children’s Research Hospital has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a tyrosine-protein kinase Lck targeting moiety via a linker acting as Lck degradation inducers reported to be useful for the treatment of cancer and immunological disorders.
RSS
